Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

Mild to Moderate Atopic Dermatitis Clinical Trial

Official title:

A Randomized, Phase 2, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of HL-009 Liposomal Gel in Adult Patients With Mild to Moderate Atopic Dermatitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01568489
• Other study ID #: HL-009-ADP2-US-01
• Status: Completed
• Phase: Phase 2
• First received: March 29, 2012
• Last updated: September 21, 2015
• Start date: March 2012
• Est. completion date: August 2013

Study information

• Verified date: September 2015
• Source: HanAll BioPharma Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The objective of this phase 2 study is to evaluate the safety and efficacy of HL-009 Liposomal Gel in adult patients with mild to moderate atopic dermatitis (AD).

Description:

This is a randomized, double-blind, placebo-controlled, parallel-group comparison study in subjects with mild to moderate AD. Following a 2-week screening period, subjects will be randomly assigned into one of four treatment arms. Placebo or HL-009 study treatments will be administrated to subjects twice daily for 8 consecutive weeks. After the randomization at Week 0 (Visit 2), subjects will visit their respective trial sites at Weeks 0.5, 1, 2, 4, 6, 8, and 10 (Visits 3, 4, 5, 6, 7, 8, and 9). All study drugs will be in identical laminated tubes to preserve double-blinding of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: August 2013
• Est. primary completion date: August 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males or females aged 18 or older

• Clinical diagnosis of AD by a board certified/eligible dermatologist

• Subjects who have body surface area affected to at least 2% total body surface area (BSA)

• Subjects with IGA score 2 or 3 corresponding to mild to moderate AD at screening and baseline visits

• Subjects who can give written informed consent

Exclusion Criteria:

• Subjects who had topical treatment with corticosteroids within 2 weeks before screening

• Subjects who had systemic treatment with corticosteroids or ciclosporin and photopheresis treatment within 2 weeks before screening

• Subjects who had ultraviolet irradiation within 2 weeks before screening

• Subjects who participated in another drug trial within 4 weeks before screening

• Subjects who have an allergy to one of the excipients

• Female subjects who have a positive serum pregnancy test at screening, plan a pregnancy during study period, or are breast feeding

• Female subjects who don't meet one of the following criteria: Be surgically sterile,Post-menopausal for at least 12 months, or If sexually active, they should use oral contraceptives, double barrier contraception, intrauterine device, or other methods approved by the sponsor

• Subjects who have other topical treatment of the AD area

• Subjects who take any systemic anti-infective or antibiotic treatment

• Subjects who had eczema herpeticum

• Subjects who have any clinically significant presence of skin disease or pigmentation other than atopic dermatitis, or wide scar on atopic dermatitis area

• Subjects who have poorly-controlled chronic disease

• Subjects who have significant medical problems, including but not limited to uncontrolled hypertension and congestive heart failure

• Subjects who have clinically significant laboratory abnormalities at screening

• Subjects who have a marked prolongation of QT/QTc interval at screening

• Subjects who have a history of additional risk factors for TdP

• Subjects who use a medication that prolongs the QT/QTc interval

• Subjects who, in the opinion of the investigator, would be non-compliant with the visit schedule of study procedures

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dermatitis
• Dermatitis, Atopic
• Eczema
• Mild to Moderate Atopic Dermatitis

Intervention

Drug:
• HL-009 Liposomal Gel
a semi-transparent red-color gel and is supplied as a laminated tube

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
HanAll BioPharma Co., Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Score change from baseline on IGA at Week 8		Weeks 0, 1, 2, 4, 6, and 8	No
Secondary	Percentage of subjects who have a minimum of 2-point improvement in IGA score at Week 8		Weeks 0, 1, 2, 4, 6, and 8	No
Secondary	Score change from baseline on EASI at Week 8		Weeks 0, 1, 2, 4, 6, and 8	No
Secondary	Score change from baseline on VAS for pruritus at Week 8		Weeks 0, 1, 2, 4, 6, and 8	No
Secondary	Score change from baseline on DLQI at Week 8		Weeks 0, 1, 2, 4, 6, and 8	No
Secondary	Score change from baseline on SF-36 questionnaires at Week 8		Weeks 0, 4, and 8	No